What is a good death? A good death follows a good life by Syed AA
What is a good death?
A good death follows a good life
Editor—A good death is like the final chap-
ter of a good book: it wraps up the story of
“life” with panache; is physically, emotion-
ally, and spiritually satisfying to the author
(the deceased) and the readers (kith and
kin); and leaves no loose ends to be
explained in a sequel.1
Akheel A Syed specialist registrar
University of Newcastle,
Newcastle upon Tyne NE2 4HH
a.a.syed@ncl.ac.uk
Competing interests: None
declared.
1 What is a good death? Join in our
online discussions. BMJ 2003;327:66.
(12 July.)
We must learn to live in
the light of our mortality
Editor—At a recent training
day on cultural awareness our
facilitator commented that
Western culture assumes
immortality, and then strives to achieve it. The
trouble is that we then come up against the
reality of death, often finding it unpalatable,
unfair, and something to be fought against.1
As Syed has already written (previous
letter),2 a good death follows a good life. His
thoughtful metaphor is very much to the
point here: not only does the final chapter
complete the story of the life that it
concludes, but every other chapter is in its
way working towards that denouement.
So a good death follows a good life, yes.
But also a good life looks forward to a death
that, hopefully, will be good. We need to live
in the light of our mortality.
Andrew G Rivett senior clinical medical officer in
health protection
Hampshire and Isle of Wight Health Protection
Unit, Southampton SO16 4GX
andrew.rivett@hiowha.nhs.uk
Competing interests: None declared.
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Death cannot be tamed
Editor—Tomorrow is not promised to any-
one young or old.1
As Heraclitus said: “Death cannot be
tamed. Death is unknown. Death is other.
Death is death. When men die there awaits
them what they neither expect nor even
imagine.”2
Mary J Curtis head of education and training
Mount Edgcumbe Hospice, St Austell, Cornwall
PL26 6AB
Mary.Curtis@Hospice.Cornwall.nhs.uk
Competing interests: None declared.
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Good death will happen if
life was good
Editor—Smith’s Editor’s
Choice should be included in
the medical literature that
students around the world
need to understand.1 A good
doctor cares for a patient’s
body and soul. Doctors must
take into consideration not
only contingent questions
related to a patient’s health condition but
also the fundamental questions about the
sense and significance of the destiny of
human beings.
We have to remember that death is the
last of our habits: a good death can be
achieved only if a patient, as well as his or
her doctor, has spent life in a “good”
manner. Where might human beings seek
the answer to dramatic questions such as
pain, the suffering of the innocent, and
death, if not in the light streaming from the
mystery of Christ’s passion, death, and
resurrection?2
Sergio Stagnaro specialist in blood, gastrointestinal,
and metabolic diseases
Via Erasmo Piaggio 23/8, 16037 Riva Trigoso,
Genova, Italy
dottsergio@libero.it
Competing interests: None declared.
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2 Pope John Paul II. Encyclical letter fides et ratio to the
bishops of the Catholic church on the relationship
between faith and reason. 14 September 1998.
A painless exit is an index of how well
you lived your life
Editor—Smith’s Editor’s Choice about the
rarity of a privileged death1 reminded me of
my father’s observation: “A painless exit is an
index of how moral and helpful your earthly
life has been.”
I have not had occasion to test its verac-
ity yet, but I think that his admonition has
kept me straight more than once.
Saty Satya Murti consulting neurologist
Topeka, KS 66601, USA
smurti@cox.net
Competing interests: None declared.
1 Smith R. Editor’s choice. Death, come closer. BMJ
2003;327. (26 July.)
The best death would be while
making love
Editor—In opera, theatre, or literature the
best deaths generally are those of brave
fighters who kill themselves to avoid capture
and degradation; the suicide of lovers
because they have, or believe they have, lost
their beloved ones; the suicide ordered by
rulers; and self sacrifice for a just cause.1
But I would rather die in my bed,making
love, quite simply.
Joseph C Watine consultant, laboratory medicine
Hôpital de Rodez, F-12027 Rodez Cédex 9, France
watine61@hotmail.com
Competing interests: None declared.
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Humour may be important even at the end
Editor—I write to contribute to the
discussion of what constitutes a good
death.1 Some years ago my colleague Peter
was dying from secondaries from a bowel
carcinoma. Looked after devotedly by his
wife and his medical carers, Peter gradually
deteriorated. However, even near the
end he was able to spend a day on his
beloved West Somerset Railway, organised
by friends.
A northerner, Peter shared a blunt,
affectionate, sense of humour with my wife,
Joan. Saying farewell, after what was to be
our last visit to him, Peter commented that
he was worn out and now just wanted to go
with dignity. With her usual speedy repartee
Joan replied: “You’ve never done anything
with dignity before, Peter. Why start now?”
Peter’s chuckles remain with us as a memory
of a very brave man and as a reminder of the
importance of laughter in our lives, even at
the end.
David F Bird general practitioner
French Weir Health Centre, Taunton TA1 1XH
dfbird@doctors.org.uk
Competing interests: None declared.
1 What is a good death? Join in our online discussions. BMJ
2003;327:66. (12 July.)
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Grandmother’s death was a good example
Editor—My grandmother was what you
could call a “grand old dame,” in terms of
dignity, not wealth. One day she decided it
was time to die. She lay down in her bed and
did not get up any more until she was
dead—three months later.1
In the years before this day, with a razor
sharp mind in a fragile body, she had often
asked if there was any way we could help her
to die. She often had health problems and
pain. However, she was happy and friendly
and still enjoyed life’s good moments, family
events, parties, etc. She lived life to the full.
When she went to a party, she exhausted
herself so much; she often had to “pay” for
days afterwards.
I visited her one month before her
death. I had to leave the country for a medi-
cal attachment in the United States, and we
both knew we would not see each other any
more. We chatted a whole afternoon, calmly
and with breaks—she was already weak. We
crowned this by having a small glass of beer
together, which she loved. She then gave me
her blessing for the future and I left. After I
had left the room I cried, but sadness and
happiness had melted into one great feeling
in my heart during this truly amazing event.
She died in her room in a nursing home
at the age of 95 years, surrounded only by a
few of her most cherished items and by my
family. I am sure she at one time had feared
the anticipation of this great last step in life,
but she died in peace, happy and content,
and grateful.
I hope I will one day be able to die up to
her standards, in dignity. I hope my family will
celebrate a good life (as so nicely put by Syed
(first letter2) on my deathbed, just like their
ancestors celebrated my birth and birthdays.
Martin Kittel general practitioner
12 Meadow Way, Dorney Reach, Maidenhead
SL6 0DS
martin.kittel@gmx.net
Competing interests: None declared.
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Life is all we have
Editor—Life is all that matters to me.1 I
would not like it shortened even by a second.
As a medical student, I have seen people who
said brave things about dignity, but when the
moment has come, they changed their
minds—they didn’t want to die. Neither do I.
I am willing to suffer. I know what pain
is. Please, dear doctors, do not take these
painful moments of life from me. Do
anything you can. Do prolong my life. It may
be painful, but it is all I have.
Nimrod Pik medical student
Tel Aviv University, Israel
nimrop@post.tau.ac.il
Competing interests: None declared.
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2003;327:66. (12 July.)
Good death may be possible in
emergency departments
Editor—The final hours of a dying patient
may be spent in an emergency department.1
In 2001, 444 patients died en route or in the
emergency departments of Edmonton,
Alberta. The number of family members
immediately affected by the disclosure of
this news while in the department is perhaps
double this or more. Family members often
experience grief when death occurs there
because the patients are often younger and
the deaths sudden and unexpected.2
Ensuring a good death while the patient
is in an emergency department is a multi-
disciplinary endeavour that requires the
help of nurses, social workers, pastoral care
workers, and doctors. In a good death the
patient’s advance directive (if he or she has
one) is respected, and the patient suffers
minimally. Also, in a good death the patient’s
emotional concerns are addressed in a
caring and compassionate manner. This
may include informing the family of the
patient’s illness.
Communicating with family members of
critically ill patients can be challenging and
stressful for both family members and health-
care providers.3 A caring and considerate
approach to communication with family
members about the patient’s condition can
perhaps help tominimise the development of
potential pathological grief responses.
Having family members present at the
bedside of the patient as he or she
undergoes resuscitation or medical care can
facilitate in communication of death and
critical illness. Family members never have
to question whether everything was done.3
The dying patient may gain emotional ben-
efit from the comfort of family presence.
Anders I Ganstal emergency physician
Royal Alexandra Hospital, Emergency
Administration, 10240 Kingsway Ave, Edmonton,
AB, Canada T5H 3V9
ganstal@telusplanet.net
Competing interests: None declared.
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3 Iserson KV. The gravest words: sudden-death notifications
and emergency care. Ann Emerg Med 2000;36:75-7.
Pathologists could provide new spaces to
say goodbye to the dead
Editor—A good death includes the way we
say goodbye to the dead person.1 However, an
appropriate environment for such goodbyes
is missing in most hospitals.2 3 This important
act has to happen in bathrooms, cold storage
chambers, or necropsy rooms. Guidelines for
establishing an appropriate environment and
the necessary equipment are lacking.
We suggest that such a room must fit
different cultures and religious persuasions.
The challenge for artists, in collaboration with
pathologists, is to create a room that is fitting
for a religious ceremony as well as a silent
atheistic ritual, without obstructing either.4
The room where relatives wait before
encountering a familiar person as a dead
body requires thought. We decided against
gentle music, favouring visual diversions
such as pictures and aphorisms on the wall
to give relatives an opportunity to look, read,
and become absorbed without embarrass-
ment. Relatives should also be informed
about the possibility of a death mask.
The room for the ceremony should
seem warm, perhaps from light falling
through a stained glass window. A crucifix,
prayer rugs, the Bible, Koran, or Torah
should be provided as required. An oppor-
tunity for ritual ablution should be given,
and there should also be a hidden sign
pointing to Mecca.
The corpse is laid out on an altar-like
square stone in the centre of the room. Its
orientation is psychologically important. It
faces the light rather than the entrance
signifying that there is no way back:
“O pleasant light, my confidence and
hope, conduct us thou,” he cried, “on this
new way.”5
Marcus Drlicek pathologist
marcus.drlicek@gespag.at
Elisabeth Langgartner student
Peter Kraml artist
Ludwig Boltzmann Institute for Neuro-oncology,
Institute of Pathology, Landes-Nervenklinik
Wagner-Jauregg, A-4020 Linz, Austria
Competing interests: None declared.
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2003;327:66. (12 July.)
2 www.medizin.uni-koeln.de/projekte/dgss/Archiv/
PC101.html
3 Drlicek M, Kraml P. Considerations on a morgue. Pathologe
2003 (in press).
4 Kraml P, ed. Kunst:Ort. Stadt Linz: Linz Kultur, 1998.
5 Dante A. The divine comedy. Purgatory, Canto XIII
www.hn.psu.edu/faculty/jmanis/dante/comedy.pdf
(accessed 28 Sep 2003).
Survival predictions may
hasten death
Editor—I have always been concerned about
predictions of death, a subject discussed by
Glare et al.1 While in some cases predictions
may be a boon to seriously ill people and
their families, in other instances they may
hasten death unnecessarily—particularly
when given months and years in advance.
Studies show that people can choose, to
some degree, the timing of their death, as
when there is a particular reason to go on
living. For example, people die more often
after a major holiday than before.2 In the lit-
erature on psychological treatments for can-
cer, when people find a reason to live, their
disease may even arrest or regress.3
On the opposite side, and here is my
concern, there is the Musselman phenom-
enon (noted first in German concentration
camps) of giving up and dying within hours.4
By predicting a death, the doctor may, in
effect, be “pointing the bone.” The literature
on hex deaths points to the possibility that
negative expectations may contribute to an
early demise.5 Negative effects of spiritual
healing may also be activated in this way.
Shamanic literature has many case reports
to this effect.5
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So a caution to those who are in the
position to be asked to predict people’s
deaths. Every prediction is based on a prob-
ability. A prediction can be stated as, “You
have a 90% probability of dying in three
months” or “You have a 10% probability of
surviving in three months.” In the comple-
mentary, alternative, healing community we
add: “So why don’t we see how we can help
you be in the 10% group, if you’d like to
work towards that goal.”
Daniel J Benor editor
International Journal of Healing and Caring—On
line (www.ijhc.org), PO Box 502, Medford, NJ
08055, USA
DB@WholisticHealingResearch.com
Competing interests: None declared.
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2 Phillips DP, King Elliot W. Death takes a holiday: mortality
surrounding major social occasions. Lancet 1988;2:728-32.
3 LeShan L. Cancer as a turning point: a handbook for people
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4 Cannon W. Voodoo death. Am Anthropol 1942;44:169-81.
5 Krippner S, Welch P. Spiritual dimensions of healing: from
native shamanism to contemporary health care. New York:
Irvington, 1992.
Responding to unexpected
events
Maybe skills for this case were missing
Editor—Saunders et al describe a difficult
and sad case, something of which they were
very aware.1 As a non-medical healthcare
professional I was acutely aware of the
absence of certain aspects of care in the case
history.
No description is provided of the techni-
cally difficult task of sitting with this man at
midnight to help him decide what he wanted
in this situation, to help him in making a
choice about the course of action that would
be consistent with his values and wishes. In
the United States clinically trained chaplains
and social workers provide this kind of
technical care. It entails skills that are not
taught in every medical school curriculum.
If patients are to “retain control of their
environment and destiny” they need the
skills of others who have been trained to
help people do that. It is not always doctors
who have best been prepared to do this.
Benefits are to be gained by having a
non-doctor function in that role.
W Noel Brown chaplain supervisor
Northwestern Memorial Hospital, Chicago,
IL 60611, USA
nbrown@nmh.org
Competing interests: None declared.
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responding to unexpected events. BMJ 2003;327:204-6.
(26 July.)
Patients have to be treated as individuals
Editor—Saunders et al discussed respond-
ing to unexpected events in planning for a
good death.1 I was recently in a very similar,
difficult, and sad situation.
My husband for 14 years had been
treated for prostate cancer for three years, in
an outpatient clinic, where he received
chemotherapy, radiotherapy, and intra-
venous isotopes, focusing on bone metas-
tases. He had no pain and was full of plans
and ideas for the future. Iliac artery
thrombosis developed; he was taken to hos-
pital and was given heparin as an antithrom-
bosis regimen. A few days after returning
home he began to have intense bleeding
from the bladder. His condition deterio-
rated, but he was full of hope, knowing that
new treatments had prolonged his life on
many occasions.
A urology specialist from another hospi-
tal decided to try to detect the cause of the
bleeds and, seeing his expectation, we trans-
ferred my husband by ambulance to a
hospital 30 km away. The bleeding came
from a ligated artery, but the mucosa of the
bladder was swollen and brittle. He was very
weak but still full of hope. Three days later
he started to have massive bleeding from the
bladder and stomach, and he died—very still,
in the presence of family, almost to the end
conscious.
I think that with every patient we have to
look at the individual person, taking into
consideration the patient’s physical, mental,
and psychological state.We cannot deprive a
patient of hope, even knowing that his or her
chances are minimal.
Halina M Iwanowska retired surgeon
S-170 77 Solna, Sweden
halina@mbox301.swipnet.se
Competing interests: None declared.
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Issues related to humanities
are close to core of science
Editor—Lewis discussed medical humani-
ties.1 Bringing humanities closer to medicine
is long overdue. Humanities introduce the
elements of reflection and qualitative
approach to increasingly commodified,
quantitative medical science. However, far
from being “soft,” issues related to humani-
ties are close to the very core of science.
An understanding of the philosophy of
science is needed to deal with issues such as
logarithmic growth of publications, peer
review,2 and the role of judgment in science.
Humanities are about communication, and
recent problems with the public image of
medicine (evident in debates on necropsy or
on pathology specimens) may have
stemmed, at least in part, from communica-
tion being inadequate. Communication in
preventive medicine translates into adher-
ence to treatment and acceptance of lifestyle
changes. Within science, good writing is fun-
damental for creating consensus.3 4
The discipline of medical humanities is a
natural place for linking the medical, arts, and
literature communities. Thismedical humani-
ties unit, formed in an NHS institution, has
since its inception acted as a networking hub.
For example, the teaching staff on the
module we offer to students at the University
of Glasgow include medical practitioners, a
philosopher, artists, historians of art and
medicine, and a medical illustrator.
Thus humanities in the medical context
benefit patients, students, and medical
science. However, I believe the true water-
shed for medical humanities will come when
leading researchers, those who wield power
in the medical faculties, decide to support
the humanities dimension in their science
oriented institutions.
Marek H Dominiczak director
Medical Humanities Unit, North Glasgow
University Hospitals NHS Trust, Gartnavel General
Hospital, Glasgow G12 0YN
mhd1b@clinmed.gla.ac.uk
Competing interests: None declared.
1 Lewis W. Medical humanities. BMJ 2003;327(suppl):s65-6.
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peer review. Nature 2003:421:111.
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another story. Nature 2003;424:128.
Everyone has own spirituality
Editor—Gatrad et al encourage the growth
of understanding of the needs of minorities.1
We are all, of course, minorities in our own
way. As they point out, each of us has a cul-
ture, and possibly a religious tradition, to
come from and to fall back on, but as they
also observe, each of us as an individual
observes and follows these in our own way.
Fundamental change in institutional
arrangements, education, and the willing-
ness of service providers (not just in health
care) to embrace complexity and diversity is
certainly required.
The move towards teaching or training in
“spirituality,” so far advanced in an avowedly
secular United States, is slowly being taken in
the United Kingdom. Our centre was com-
missioned to review the research literature
and evidence on spirituality in health by the
Leicester health action zone, and much of the
resultant material is recorded on our website
(http://users.wbs.ac.uk/group/ceehd/home/
end_of_life).
The journey of a thousand miles begins
with the first step, and that means the
personal realisation by all healthcare profes-
sionals that their clients will have their own
spirituality—however we, and they, may
define that.
Mark R D Johnson professor of diversity in health
and social care
johnsons@cv77dq.freeserve.co.uk
Kip Jones Economic and Social Research Council
fellow in qualitative evidence in ethnicity and health care
Centre for Evidence in Ethnicity Health and
Diversity, Mary Seacole Research Centre,
De Montfort University, Leicester LE2 1RQ
Competing interests: MRDJ is director of a
research centre dedicated to promoting evidence
based “cultural competence” and a contributor
to a proposed national resource of the training
of healthcare professionals in transcultural
healthcare practice.
1 Gatrad AR, Brown E, Notta H, Sheikh A. Palliative care
needs of minorities: Understanding their needs is the key.
BMJ 2003;327:176-7. (24 July.)
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ATAC trial did not report
interim results
Editor—We agree with Goodare et al that it
is inappropriate to publish interim analyses.1
However, the results of the ATAC (arimidex,
tamoxifen, alone or in combination) trial
published in the Lancet were the first major
analysis as fully defined in the protocol, not
an interim analysis.2
The statistical power of the trial, defined
in the protocol, determined that this analysis
would be triggered at 1056 events. Using
first event as the primary end point in breast
cancer trials is widespread since it is highly
likely to predict later survival.
Data from the first analysis of the ATAC
trial indicated the potential superiority in
efficacy and overall tolerability of anastro-
zole over tamoxifen as adjuvant treatment
for postmenopausal women with early
breast cancer. However, it also showed the
disappointing performance of the arm
receiving combined treatment, which the
independent data monitoring committee
advised us to close, to limit exposure of trial
participants to two drugs when one would
do. Informing patients of the early results
has not had an adverse effect, as drop out
rate has been very low.
The reporting of the positive or
negative results of a pre-planned analysis is
not only good science, but also informs
breast cancer patients about potential new
therapies. The results of the ATAC trial pro-
vide, for the first time, an alternative to
tamoxifen for women with early breast
cancer—a breakthrough for both science
and patients. This study will continue to
define the therapeutic index of anastrozole
versus tamoxifen with additional follow up.
Michael Baum visiting professor of medical
humanities
Clinical Trials Group, Department of Surgery,
University College London, London W1W 7EJ
Aman Buzdar doctor
Department of Medical Oncology, Medical Breast
Cancer Service, University of Texas, MD Anderson
Cancer Center, Houston, TX 77030, USA
Anthony Howell professor of medical oncology
Department of Medical Oncology, Cancer Research
UK, University of Manchester, Manchester M20 4BX
Competing interests: None declared.
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Group of the Department of Surgery, University
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Hoed Kliniek and University Hospital Rotterdam,
Rotterdam, Netherlands; Gershon Locker, Evanston
Hospital, Kellogg Cancer Care Center, Evanston, IL,
USA; John Mackey, Cross Cancer Institute, Edmon-
ton, Canada; Robert Mansel, University of Wales
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Richard Sainsbury, Royal Free and University
College Medical School, London; Jeffrey Tobias,
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Clinical Trials Group of the Department of Surgery,
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1 Goodare H, Dimmer C, Page K. ATAC trial: reporting
interim results is not helpful. BMJ 2003;326:1329.
(12 June.)
2 The ATAC Trialists’ Group. Anastrozole alone or in
combination with tamoxifen versus tamoxifen alone for
adjuvant treatment of postmenopausal women with early
breast cancer: first results of the ATAC randomised trial.
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Respiratory hazards of “nail
sculpture”
Editor—We report our concern about the
respiratory hazards of “nail sculpture.”
From October 2001 to August 2002 we
identified in the Yorkshire and north
Lincolnshire area three cases of respiratory
ill health (work related wheezing, tight chest)
related to nail sculpture, a work activity
which we think is growing in popularity; it
entails using resins to improve the cosmetic
appearance of fingernails.
Acrylic resins were the predominant
(though not exclusive) resin type used.
Although all three women had received
training, none had been warned of the poten-
tial for adverse respiratory effects. Two of the
three abandoned the work with improvement
of symptoms; the other was able to continue
after changing to another resin.
The respiratory hazards of using acrylic
resins and applying artificial nails are well
documented.1 2 Nail dust has also been asso-
ciated with respiratory problems.3 We hope
that this letter will alert family doctors, respi-
ratory physicians, and others to this occupa-
tional hazard. Advice on applying artifical
nails, from which useful comparison with
nail sculpture can be drawn, is obtainable on
the US government website http://www.
cdc.gov/niosh/hc28.html
Frank Gallagher medical inspector of safety and
health
frank.gallagher@hse.gsi.gov.uk
Diana Gaubert medical inspector of safety and health
Health and Safety Executive, Edgar Allen House,
Sheffield S10 2GW
Michael Hale senior health and safety inspector
North East Lincolnshire Council, Environmental
Services, Commercial Section, Freeman House,
Grimsby DN32 7AU
Competing interests: None declared.
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Tamoxifen is unproved for
gynaecomastia
Editor—We were amazed at Khan and
Blamey’s recommendation of tamoxifen as
first line treatment of gynaecomastia.1 This
drug does not have a product licence for
such treatment.The evidence base for their
conclusion is small (135 patients) and is
certainly not derived from randomised
controlled clinical trials.
Gynaecomastia is most common in
pubertal boys, in whom the condition is
usually self-limiting,2 and data are insuffi-
cient to show that tamoxifen is safe in this
group of patients. Many questions remain
unanswered.
What effect does it have on bone
growth? Does the gynaecomastia come back
after stopping treatment? What is the
optimum duration of treatment?
This editorial is misleading, and until
more evidence shows that tamoxifen is safe
in this condition it should not be recom-
mended as first line treatment, especially in
pubertal boys.
Julie C Doughty honorary senior lecturer
dr37d@udcf.gla.ac.uk
Christopher R Wilson consultant surgeon
Department of Surgery, Western Infirmary,
Glasgow G11 6NT
Competing interests: None declared
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Small risk ratios may have
strong public health impact
Editor—Traversa et al studied the hepa-
toxicity of nimesulide and other non-
steroidal anti-inflammatory drugs (NSAIDs).1
Nimesulide may arguably have a small risk of
the more severe hepatic injuries with an odds
ratio of 1.9 (95% confidence interval 1.1 to
3.81). Since the drug is widely used in Italy the
population attributable risk could account for
a number of avoidable cases.2
The characteristics of users of the differ-
ent NSAIDs were assumed to be similar on
the basis of the numbers of packets per pre-
scription. If, rather than the number of
packets, the number of defined daily doses
per person had been used—a more reliable
approach—the conclusion would have been
different since the mean number of defined
daily doses per user of nimesulide and
NSAIDs were 50.9 and 73.2, respectively.
A substantial proportion of nimesulide
induced hepatotoxicity occurred after a
comparatively long time of exposure. In
Spain five of the 11 most severe cases of
hepatotoxicity related to nimesulide
occurred after more than one month of
treatment3; the average duration until occur-
rence in a series of 13 published cases of
severe hepatotoxicity was 62 days.4
Nimesulide does not seem to have any
demonstrated advantage over the most
widely used NSAIDs in efficacy or safety. This
Letters
1050 BMJ VOLUME 327 1 NOVEMBER 2003 bmj.com
was shown for upper gastrointestinal compli-
cations by García-Rodríguez et al in a
case-control study performed in Italy
(nimesulide: odds ratio 4.4, 2.5 to 7.7; ibupro-
fen: odds ratio 2.1, 0.6 to 7.1; diclofenac: odds
ratio 2.7, 1.5 to 4.8).5
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Non-pharmacological options
may have role in
postmenopausal osteoporosis
Editor—Cranney’s editorial thoroughly
covered the pharmacological options avail-
able for treating postmenopausal osteo-
porosis.1 Non-pharmacological treatments
may also have a role, given the uncertainties
in managing osteoporosis.
Exercise is a simple intervention that can
be advised for postmenopausal women with
osteoporosis and is beneficial for other
health issues as well. Several systematic
reviews have shown an increase in bone
mineral density.2
Another key issue is the need to decrease
the risk of falling. Systematic reviews show the
effectiveness of measures to prevent falls, and
evidence shows that some available interven-
tions are likely to be effective.3
In the last update of a review about hip
protectors the initial beneficial effect
observed was not confirmed from studies
using individual randomisation.4 Another
issue is that most trials targeted people at
particularly high risk of fracture.
Head to head comparisons are
required, however, and not just among
pharmacological options. Results from the
women’s health initiative trial have made
clear that we need to be cautious about the
long term effects as sometimes harms
might surprisingly outweigh benefits.5
How long are we going to keep treating
patients with these drugs? Will we have to
tell them to stop because of new unexpected
adverse effects? Women who are taking a
treatment might change their mind if they
knew how little we know about the actual
benefit they might be obtaining.
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Costs and effectiveness of
prehospital thrombolysis need
to be clear
Editor—Pedley et al provide further evi-
dence that paramedical staff providing
prehospital thrombolysis for acute myo-
cardial infarction is feasible and reduces the
treatment delay.1 However, no cost data were
presented.
The authors say that two extra lives
might be expected to be saved per 100
patients treated. It is unclear how this
estimate was derived. We suspect that this is
from the meta-analysis by Boersma et al.2
Importantly, this health benefit of a one
hour reduction in the treatment delay must
be within three hours from symptom onset.
Pedley et al describe collecting times of
onset of symptoms but do not present their
results. This is an important omission as the
mortality benefit of thrombolysis is directly
related to treatment delay from the time of
the onset of symptoms. The health benefit of
a one hour decrease in treatment delay will
be considerably reduced if the total delay is
longer than three hours.2
Evidence from audit that the care
pathway for acute myocardial infarction is
achieving the maximum possible health
benefit is needed before considering intro-
ducing a prehospital thrombolysis service.
We believe that the emphasis of research
should now move to establishing and evalu-
ating cost effective models of care for
prehospital thrombolysis rather than feasi-
bility studies. Proposals for a prehospital
thrombolysis service will be competing
against other healthcare interventions in the
prioritisation process of primary care trusts.
Therefore the costs and effectiveness of such
a service will need to be clear and robust to
achieve long term funding.
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Equality for people with
disabilities in medicine
Editor—The view of the General Medical
Council in respect of students with dis-
abilities going to medical school is crystal
clear and very positive.
We believe that students with a wide
range of disabilities can—and we know that
they do—successfully complete the medical
curriculum. We would become concerned
only in the rare instances where public safety
might be at risk. This is spelt out in
Tomorrow’s Doctors.1 Being in a wheelchair,
for example, should not of itself be a bar to
studying medicine, and I am personally
aware of one such student who recently
began their medical studies.
I set this position out in the Career
Focus of 18 October.2 I was therefore
surprised and disappointed by the editorial
in the same issue of the BMJ 3 because it gave
the erroneous impression that the GMC
gets in the way of students with disabilities
going to medical school—we don’t. Since the
editorial was not cross referenced to my arti-
cle, despite my article having been commis-
sioned by one of the authors of the editorial,
quite the wrong message was conveyed.
The editorial is also misleading in its
references to the Heidi Cox case by stating
that she “won her initial complaint” against
a “ruling” by the GMC that she should not
study medicine.3 This is incorrect. Ms Cox
has never won any complaint against the
GMC and her case had no basis in law.
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*** We apologise for unintentionally missing
out the link from the editorial by Mercer et al
to Professor Rubin’s article. We published it
in a rapid response to the editorial (bmj.
bmjjournals.com/cgi/eletters/327/7420/
882[38388). The link is bmj.bmjjournals.
com/cgi/content/full/327/7420/s123
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